- Sort by:
- Browse by:
- Permission not
granted for presentation
Epigenetic drivers and vulnerabilities in small-cell lung cancer
David Macpherson
Fred Hutchinson Cancer Research Ctr., Seattle, WA, United States
- Free
- audio + slides
- Some slides withheld
Metabolic vulnerabilities in MYC-driven small cell-lung cancer
Trudy G Oliver
Univ. of Utah Huntsman Cancer Inst., Salt Lake City, UT, United States
- Free
- slides video
- audio + slides
- All slides included
A tuft cell variant of small-cell lung cancer
Christopher R Vakoc
Cold Spring Harbor Laboratory Cancer Ctr., Cold Spring Harbor, NY, United States
- Permission not
granted for presentation
Epigenomic approaches to identify transcriptional dependencies in prostate cancer
Qianben Wang
Duke University, Durham, NC, United States
- Free
- slides video
- audio + slides
- All slides included
Cistrome mining for new therapeutic targets in hormone-dependent cancers
Myles A Brown
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Long-range epigenetic control of estrogen-responsive transcription
Tim Hui-Ming Huang
UT Health Science Ctr. at San Antonio, San Antonio, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Lessons from agriculture for how to manage therapeutic resistance
Carlo C Maley
Arizona State Univ., Tempe, AZ, United States
- Free
- slides video
- audio + slides
- All slides included
Personalized adaptive therapy for metastatic cancer: An integrated approach
Alexander R. A. Anderson
Moffitt Cancer Center, Tampa, FL, United States
- Permission not
granted for presentation
From evolutionary mathematical modeling to clinical validation in glioblastoma patients: Lessons learned
Franziska Michor
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Genomics of multifocal small intestinal neuroendocrine tumors
Matthew L Meyerson
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- audio + slides
- Some slides withheld
Systematic identification and pharmacologic targeting of GEP-NET dependencies
Andrea Califano
Columbia Univ., New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Translational research in neuroendocrine tumors: Implications for clinical trial design
Emily K Bergsland
UCSF Helen Diller Family Comp. Cancer Ctr., San Francisco, CA, United States
- Free
- Coming soon
- Some slides withheld
Overview of thyroid cancer: Epidemiology to state-of art standard of care
Steven I. Sherman
UT MD Anderson Cancer Center, Houston, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Cancer genomics: Well to poorly differentiated thyroid carcinoma
James A Fagin
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Discovering targeted therapies of thyroid cancer using drosophila models
Ross L Cagan
Mount Sinai School of Medicine, New York, NY, United States
- Free
- audio + slides
- Some slides withheld
BRAF-targetedtherapy and mechanisms of resistance in thyroid cancer clinical trials
Manisha H Shah
Ohio State Univ. Comp. Cancer Ctr., Columbus, OH, United States
- Free
- slides video
- audio + slides
- All slides included
Emerging novel RET-Targeted therapy in thyroid cancer
Lori J Wirth
Massachusetts General Hospital, Boston, MA, United States
- Free
- audio + slides
- Some slides withheld
Mechanisms of acquired therapeutic resistance in SCLC
Charles M Rudin
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Targeting DNA damage response and immune checkpoints in SCLC
Lauren Averett Byers
UT MD Anderson Cancer Ctr., Houston, TX, United States
- Free
- audio + slides
- Some slides withheld
Tumor heterogeneity and therapy response in SCLC
Julien Sage
Stanford Univ. School of Medicine, Stanford, CA, United States
- Permission not
granted for presentation
Invited Speaker
Yibin Kang
Princeton Univ., Princeton, NJ, United States
- Free
- audio + slides
- All slides included
Chairperson
James A DeCaprio
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- audio + slides
- Some slides withheld
The genomics and epigenomics of merkel cell carcinoma
Paul W. Harms
University of Michigan, Ann Arbor, MI, United States
- Free
- slides video
- audio + slides
- All slides included
UV induced mutations and polyomavirus target similar pathways in Merkel cell carcinoma
James A DeCaprio
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Immune therapy for Merkel cell carcinoma: Progress and challenges
Paul Nghiem
Univ. of Washington, Seattle, WA, United States